Clinical Trial Update: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating olaparib monotherapy for metastatic breast cancer focused on HER2-negative disease with germline BRCA1/2 mutations; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations | Phase 3 | Status: COMPLETED | Results posted: 2023-01-17